Back to library
Loading…
glp1 · The Lancet Diabetes & Endocrinology · 2021
This meta-analysis and systematic review found that GLP-1 receptor agonists reduce the risk of major adverse kidney events and improve estimated glomerular filtration rate in patients with type 2 diabetes.
Sattar N, Lee MMY, Kristensen SL, et al.
This meta-analysis and systematic review found that GLP-1 receptor agonists reduce the risk of major adverse kidney events and improve estimated glomerular filtration rate in patients with type 2 diabetes.